EGFR and neoplasm: Indeed, by targeting EGFR the TPCS2a-PDT-resistance is significantly reduced regardless of the tumor adaptation respecting the cell death mechanism (e.g. apoptosis, necroptosis, or autophagy), Figure 2 (76).